Get it on Google Play

Rocket Pharmaceuticals updates RP-A501 Danon disease trial data

October 7, 2026 9:36 AM EDT Send to a Friend
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) released updated clinical findings for its gene therapy candidate RP-A501, targeting Danon disease, following an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login